@entity715 in @entity706 XXXX and in @entity1582 @entity1 .

@entity1 @entity706 @entity1581 @entity5 @entity117 @entity1749 @entity1582 @entity1583 @entity1893 @entity715 @entity978 @entity1211
UNASSIGNED: The risk of @entity1211 ( @entity1211 ) in @entity1 with @entity5 is several-fold higher than that in individuals without @entity5 . Recent studies demonstrated a high incidence of @entity1211 in @entity1 with @entity1583 as well as in @entity1 with solid @entity5 . The reported incidence of @entity1211 in @entity706 is variable, ranging from less than 5% to 59.5%. The incidence of @entity1211 is higher in @entity1893 than it is in @entity978 . The incidence of @entity1211 also varies according to the disease grade, the disease stage, the performance status of the @entity1 , and the site of disease. Most @entity1211 cases occur at the diagnosis of @entity5 or early in the course of @entity5 treatment. An elevated incidence of @entity1211 is also reported in cases of @entity1582 . @entity1211 occurs in approximately 5% of @entity1582 @entity1 treated with conventional chemotherapy, and treatment of @entity1582 @entity1 with immunomodulatory drugs (IMid)-based therapy increases the risk of @entity1211 . Prophylactic @entity117 or anticoagulant is used in @entity1582 @entity1 treated with IMid-based therapy. Several reports have indicated that the incidence of @entity1211 is relatively low in Asian @entity1 treated with IMid-based therapy, and concomitant use of @entity1749 reduces the risk of @entity1211 . The incidence of @entity715 is also increased in @entity1 with @entity1582 and @entity1581 of undetermined significance. Further studies are needed to develop a predictive model for identifying @entity1 with @entity706 and @entity1582 who are at high risk for developing @entity715 .
